Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new weekly shot boost weight loss beyond current therapies?

NCT ID NCT07776509

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether an experimental drug called AZD6234, given as a weekly injection, can help adults with obesity or overweight lose more weight when added to their current incretin-based therapy. The study includes about 500 participants who either have type 2 diabetes or not, and compares the drug against a placebo over 68 weeks. The main goal is to see how much body weight changes from the start of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD6234, an experimental drug injected once a week under the skin
What this could lead to
If successful, this could offer a new add-on treatment option to help people with obesity or overweight achieve greater weight loss when combined with existing incretin-based therapies.
What could go wrong
This is an early-stage phase 3 trial, so results may not confirm benefit or safety. Possible side effects and individual responses vary, and the drug may not be approved or widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * For participants with T2DM only: * Diagnosed with T2DM ≥ 90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤9.0% (75 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent and/or incretin-based medication * Receiving a stable dose of incretin- based medications at a dose level that is sufficient for chronic weight management for at least 3 months prior to Screening and Randomisation. * Stable body weight (≤ 3% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Use of insulin therapy for T2DM within 3 months prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity or overweight Weight-related comorbidity With/without diabetes mellitus, type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    88 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    Escondido, California, 92025, United States

  • Research Site

    Lincoln, California, 95648, United States

  • Research Site

    Walnut Creek, California, 94598, United States

  • Research Site

    Fleming Island, Florida, 32003, United States

  • Research Site

    Jacksonville, Florida, 32205, United States

  • Research Site

    Stockbridge, Georgia, 30281, United States

  • Research Site

    Woodstock, Georgia, 30189, United States

  • Research Site

    Champaign, Illinois, 61822, United States

  • Research Site

    Chicago, Illinois, 60640, United States

  • Research Site

    Beltsville, Maryland, 20705, United States

  • Research Site

    Oxon Hill, Maryland, 20745, United States

  • Research Site

    Kansas City, Missouri, 64111, United States

  • Research Site

    Las Vegas, Nevada, 89101, United States

  • Research Site

    Somerset, New Jersey, 08873, United States

  • Research Site

    Statesville, North Carolina, 28625, United States

  • Research Site

    Fargo, North Dakota, 58104, United States

  • Research Site

    Columbus, Ohio, 43215, United States

  • Research Site

    Portland, Oregon, 97202, United States

  • Research Site

    Smithfield, Pennsylvania, 15478, United States

  • Research Site

    Franklin, Tennessee, 37067, United States

  • Research Site

    Houston, Texas, 77043, United States

  • Research Site

    Manassas, Virginia, 20110, United States

  • Research Site

    Renton, Washington, 98057, United States

  • Research Site

    CABA, C1120AAC, Argentina

  • Research Site

    CABA, C1425HFA, Argentina

  • Research Site

    Ciudad de Buenos Aires, B1704ETD, Argentina

  • Research Site

    Ciudad de Buenos Aires, C1094AAD, Argentina

  • Research Site

    Rosario, S2000PBJ, Argentina

  • Research Site

    San Nicolás, B2900DMH, Argentina

  • Research Site

    Belo Horizonte, 30150-320, Brazil

  • Research Site

    Campinas, 13060-080, Brazil

  • Research Site

    Campinas, 13060-904, Brazil

  • Research Site

    São Paulo, 01236-030, Brazil

  • Research Site

    São Paulo, 04039-002, Brazil

  • Research Site

    São Paulo, 04266-010, Brazil

  • Research Site

    Calgary, Alberta, T2V 4J2, Canada

  • Research Site

    Calgary, Alberta, T3R 1W9, Canada

  • Research Site

    Surrey, British Columbia, V3T 4G8, Canada

  • Research Site

    Vancouver, British Columbia, V5Y 3W2, Canada

  • Research Site

    Guelph, Ontario, N1H 1B1, Canada

  • Research Site

    Hamilton, Ontario, L8L 5G8, Canada

  • Research Site

    Stouffville, Ontario, L4A1H2, Canada

  • Research Site

    Toronto, Ontario, M4G3E8, Canada

  • Research Site

    Joliette, Quebec, J6E 6A9, Canada

  • Research Site

    Montreal, Quebec, H4J 1E3, Canada

  • Research Site

    Nanjing, 210008, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Ningbo, 315000, China

  • Research Site

    Aarhus N, 8200, Denmark

  • Research Site

    Gandrup, 9362, Denmark

  • Research Site

    Herlev, 2730, Denmark

  • Research Site

    Holbæk, 4300, Denmark

  • Research Site

    Hvidovre, 2650, Denmark

  • Research Site

    Odense, 5000, Denmark

  • Research Site

    Vejle, 7100, Denmark

  • Research Site

    Holon, 5822012, Israel

  • Research Site

    Jerusalem, 00000, Israel

  • Research Site

    Kfar Saba, 4428164, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Petah Tikva, 4937211, Israel

  • Research Site

    Tel Aviv, 64239, Israel

  • Research Site

    Chūōku, 103-0002, Japan

  • Research Site

    Ichinomiya-shi, 491-8558, Japan

  • Research Site

    Izunokuni-shi, 410-2295, Japan

  • Research Site

    Kamakura-shi, 247-0056, Japan

  • Research Site

    Kawagoe-shi, 350-0851, Japan

  • Research Site

    Kitakyushu-shi, 802-0077, Japan

  • Research Site

    Kyoto, 607-8062, Japan

  • Research Site

    Kyoto, 612-8555, Japan

  • Research Site

    Mito, 311-4153, Japan

  • Research Site

    Nishinomiya-shi, 662-0971, Japan

  • Research Site

    Ōmihachiman, 523-0082, Japan

  • Research Site

    Yokohama, 230-8765, Japan

  • Research Site

    Linköping, 58213, Sweden

  • Research Site

    Lund, 222 22, Sweden

  • Research Site

    Mölndal, 43153, Sweden

  • Research Site

    Örebro, 703 62, Sweden

  • Research Site

    Stockholm, 113 61, Sweden

  • Research Site

    Ankara, 06100, Turkey (Türkiye)

  • Research Site

    Ankara, 06800, Turkey (Türkiye)

  • Research Site

    Antalya, 07059, Turkey (Türkiye)

  • Research Site

    Center, 23200, Turkey (Türkiye)

  • Research Site

    Istanbul, 34384, Turkey (Türkiye)

  • Research Site

    Airdrie, ML6 0JS, United Kingdom

  • Research Site

    Chippenham, SN14 6GT, United Kingdom

  • Research Site

    Hull, HU3 2PA, United Kingdom

  • Research Site

    Llandough, CF64 2XX, United Kingdom

  • Research Site

    Rotherham, S65 1DA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.